title: Agonist diversity in 5-HT(2C) receptor-mediated weight control in rats.
abstract: BACKGROUND
  Food intake and energy expenditure are the two main determinants of body weight. Given that 5-HT(2C) receptor agonists are reported to have effects on both energy expenditure and food intake, this strongly suggests that 5-HT(2C) receptor agonists have excellent potential for development as antiobesitiy drugs. One important issue in antiobesity drug development is whether the effects of the compound are maintained during chronic drug treatment.
  
  
  OBJECTIVE
  The purpose of the present study was to investigate the effect of repeated oral administration of three 5-HT(2C) receptor agonists, m-chlorophenylpiperazine (mCPP), d(S)-2-(6-chloro-5-fluoroindol-1-yl)-1-methylethylamine (RO60-0175) and (S)-2-(7-ethyl-1H-furo[2,3-g]indazol-1-yl)-1-methylethylamine (YM348), on food intake and energy expenditure in rats.
  
  
  RESULTS
  In the food intake study, mCPP, RO60-0175 and YM348 decreased food intake in a dose-dependent manner on day 1 of administration. On day 14 of repeated administration, the hypophagic effect of YM348 was lost and that of mCPP was reduced. In contrast, the hypophagic effect of RO60-0175 was maintained even after repeated administration. The hypophagic effects of all agonists were significantly inhibited by a 5-HT(2C) receptor antagonist, SB242084. In contrast to the hypophagic effects, no drug tolerance developed with respect to the hyperthermic effects of mCPP, RO60-0175, and YM348. The hyperthermic effects of these drugs were also inhibited by SB242084.
  
  
  CONCLUSIONS
  Together, the difference between compounds in their hypophagic effects and the similarity in their hyperthermic effects suggest a diversity in agonists in 5-HT(2C) receptor-mediated weight control in rats.
authors.affiliation: Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd, 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan. hayashi.asuka@yamanouchi.co.jp
authors.forename: Aska
authors.initials: A
authors.lastname: Hayashi
authors.forename: Masanori
authors.initials: M
authors.lastname: Suzuki
authors.forename: Masao
authors.initials: M
authors.lastname: Sasamata
authors.forename: Keiji
authors.initials: K
authors.lastname: Miyata
mesh_terms: D000284:Administration, Oral; D000631:Aminopyridines / Q000494:pharmacology; D000818:Animals; D001067:Appetite Depressants / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004734:Energy Metabolism / Q000187:drug effects*; D005021:Ethylamines / Q000494:pharmacology; D005247:Feeding Behavior / Q000187:drug effects*; D007191:Indazoles; D007211:Indoles / Q000494:pharmacology; D008297:Male; D010879:Piperazines / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D058826:Serotonin 5-HT2 Receptor Agonists; D015431:Weight Loss / Q000187:drug effects*
chemical_list: C107820:6-chloro-5-methyl-1-((2-(2-methylpyrid-3-yloxy)pyrid-5-yl)carbamoyl)indoline; D000631:Aminopyridines; D001067:Appetite Depressants; D005021:Ethylamines; D007191:Indazoles; D007211:Indoles; D010879:Piperazines; C103848:Ro 60-0175; D058826:Serotonin 5-HT2 Receptor Agonists; C488691:YM348; C015068:1-(3-chlorophenyl)piperazine
references.citation: Physiol Behav. 1982 Sep;29(3):553-9
references.pmid: 7178261
references.citation: Neuropharmacology. 2001 Aug;41(2):200-9
references.pmid: 11489456
references.citation: Neuropharmacology. 1997 Feb;36(2):233-9
references.pmid: 9144661
references.citation: J Pharmacol Exp Ther. 1998 Aug;286(2):913-24
references.pmid: 9694950
references.citation: Trends Pharmacol Sci. 1995 Jul;16(7):232-8
references.pmid: 7667897
references.citation: Neuropharmacology. 1994 Mar-Apr;33(3-4):261-73
references.pmid: 7984266
references.citation: Psychopharmacology (Berl). 2000 Oct;152(3):256-67
references.pmid: 11105935
references.citation: Br J Pharmacol. 1988 May;94(1):137-47
references.pmid: 3401632
references.citation: Neuropharmacology. 1994 Mar-Apr;33(3-4):275-317
references.pmid: 7984267
references.citation: J Pharmacol Exp Ther. 1994 Oct;271(1):143-8
references.pmid: 7965707
references.citation: Biochem Pharmacol. 2001 Aug 15;62(4):431-8
references.pmid: 11448452
references.citation: J Neurosci. 2000 Nov 15;20(22):8637-42
references.pmid: 11069973
references.citation: Trends Pharmacol Sci. 1998 Jul;19(7):270-6
references.pmid: 9703760
references.citation: Biochem Biophys Res Commun. 2002 Jul 12;295(2):249-54
references.pmid: 12150939
references.citation: Clin Ther. 2003 Jan;25(1):58-80
references.pmid: 12637112
references.citation: Mol Pharmacol. 1998 Jul;54(1):94-104
references.pmid: 9658194
references.citation: J Pharmacol Exp Ther. 2002 Sep;302(3):957-62
references.pmid: 12183652
references.citation: Mol Endocrinol. 1994 Apr;8(4):518-27
references.pmid: 7914350
references.citation: Brain Res. 2004 Jun 18;1011(2):221-7
references.pmid: 15157808
references.citation: Diabetes Obes Metab. 2000 Jun;2(3):175-87
references.pmid: 11220553
references.citation: Neuropharmacology. 1999 Aug;38(8):1083-152
references.pmid: 10462127
references.citation: Eur J Pharmacol. 1995 Dec 7;293(4):309-17
references.pmid: 8748683
references.citation: Int J Obes Relat Metab Disord. 1999 Jul;23(7):669-77
references.pmid: 10454099
references.citation: J Biol Chem. 1997 Jul 11;272(28):17686-93
references.pmid: 9211919
references.citation: Pharmacol Biochem Behav. 1988 Jun;30(2):451-6
references.pmid: 2971978
references.citation: Br J Pharmacol. 1998 Apr;123(8):1707-15
references.pmid: 9605579
references.citation: Psychopharmacology (Berl). 2003 May;167(3):274-80
references.pmid: 12690422
references.citation: Eur J Pharmacol. 2004 Jan 1;483(1):37-43
references.pmid: 14709324
references.citation: Br J Pharmacol. 1998 Oct;125(4):727-34
references.pmid: 9831908
references.citation: Brain Res Bull. 1982 Jun;8(6):645-51
references.pmid: 7139357
references.citation: Psychopharmacology (Berl). 2001 Sep;157(3):292-8
references.pmid: 11605085
references.citation: Am J Physiol. 1989 Dec;257(6 Pt 2):R1322-7
references.pmid: 2690646
references.citation: Psychopharmacology (Berl). 1996 Feb;123(4):333-9
references.pmid: 8867872
references.citation: Nature. 1995 Apr 6;374(6522):542-6
references.pmid: 7700379
references.citation: Eur J Pharmacol. 2000 Jan 10;387(2):197-204
references.pmid: 10650160
references.citation: Science. 2002 Jul 26;297(5581):609-11
references.pmid: 12142539
references.citation: Br J Pharmacol. 1998 Jun;124(4):763-71
references.pmid: 9690869
references.citation: Br J Pharmacol. 2000 Jul;130(6):1305-14
references.pmid: 10903970
references.citation: Arch Intern Med. 2000 Jul 24;160(14):2185-91
references.pmid: 10904462
references.citation: Psychopharmacology (Berl). 1988;96(1):93-100
references.pmid: 2906446
references.citation: Pharmacol Biochem Behav. 2000 Oct;67(2):291-305
references.pmid: 11124393
references.citation: J Neurochem. 1995 Jun;64(6):2473-9
references.pmid: 7760026